CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
LUM001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02061540
NCT02061540Phase 2Completed
CompareCT.gov

A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis

Mirum Pharmaceuticals, Inc.·interventional·Posted Feb 13, 2014·Updated Mar 29, 2019

In Brief

A Phase 2 clinical trial evaluating LUM001 for Primary Sclerosing Cholangitis (PSC). Completed, enrolled 27 participants across 9 sites in 3 countries.

Detailed Summary

The study is an open-label study in adults with primary sclerosing cholangitis to evaluate the safety, tolerability, and effect of 14-weeks of daily dosing of LUM001.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Sclerosing Cholangitis (PSC)
CountriesCanada, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 13, 2014
Enrollment StartMar 1, 2014
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.4 years ago

Interventions

LUM001drug

LUM001 oral dose